rs121917761
Variant summary
Our verdict is Likely pathogenic. Variant got 8 ACMG points: 8P and 0B. PM1PM2PP3_Strong
The ENST00000344887.10(TNNI3):c.511G>A(p.Ala171Thr) variant causes a missense change. The variant allele was found at a frequency of 0.000000685 in 1,460,592 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. A171V) has been classified as Uncertain significance.
Frequency
Consequence
ENST00000344887.10 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 8 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
TNNI3 | NM_000363.5 | c.511G>A | p.Ala171Thr | missense_variant | 7/8 | ENST00000344887.10 | NP_000354.4 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
TNNI3 | ENST00000344887.10 | c.511G>A | p.Ala171Thr | missense_variant | 7/8 | 1 | NM_000363.5 | ENSP00000341838 | P1 |
Frequencies
GnomAD3 genomes Cov.: 31
GnomAD4 exome AF: 6.85e-7 AC: 1AN: 1460592Hom.: 0 Cov.: 32 AF XY: 0.00000138 AC XY: 1AN XY: 726642
GnomAD4 genome Cov.: 31
ClinVar
Submissions by phenotype
Cardiomyopathy, familial restrictive, 1 Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Jan 01, 2003 | - - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Dec 28, 2021 | Variant summary: TNNI3 c.511G>A (p.Ala171Thr) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 248984 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.511G>A has been reported in the literature in an individual affected with Restrictive Cardiomyopathy who was an only child and no clinical data or DNA was available on his deceased parents (example, Mogensen_2003). None of his children were identified as carriers of this variant. It has also been reported with a likely pathogenic classification in an individual reportedly affected with hypertrophic cardiomyopathy (HCM) within the Oxford Medical Genetics Laboratories (OMGL) testing cohort (example, Walsh_2017). These report(s) do not provide unequivocal conclusions about association of the variant with Restrcitve/Hypertrophic Cardiomyopathy. At-least two publications report experimental evidence evaluating an impact on protein function (example, Gomes_2005, Yumoto_2005), however, none of these studies allows convincing conclusions about the variant effect. Briefly summarized, this variant demonstrated an increase in Calcium sensitivity of force development compared with WT cTnI, caused a decrease in ability of cTnI to inhibit actomyosin ATPase activity and using mixtures of WT and mutant cTnI, this variant was classified into the dominant group (along with two other variants) in actomyosin ATPase assays in the absence of calcium ion. Most of the mutants were able to activate actomyosin ATPase similarly to wild-type. As represented, the data on this variant do not allow unequivocal contributions to ascertain as a strong evidence surrounding the pathophysiology of disease. One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation and classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. - |
Hypertrophic cardiomyopathy Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 19, 2023 | Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. ClinVar contains an entry for this variant (Variation ID: 12429). This missense change has been observed in individual(s) with restrictive cardiomyopathy or hypertrophic cardiomyopathy (PMID: 12531876, 27532257, 30384889). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces alanine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 171 of the TNNI3 protein (p.Ala171Thr). Experimental studies have shown that this missense change affects TNNI3 function (PMID: 15961398, 16288990, 18423659). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at